330175 Echinomycin Streptomyces sp. - CAS 512-64-1 - Calbiochem

330175
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₅₁H₆₄N₁₂O₁₂S₂ 512-64-1

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
330175-1MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable Streptomyces-derived antibiotic that contains two bicyclic peptide-linked quinoxalines and acts as a sequence-specific DNA bisintercalator. Echinomycin at 10 µM is shown to inhibit HIF-1 and Myc/Max DNA binding activities in U251 and MCF-7 nuclear extracts by >90%, while exhibiting little effect against the binding of AP-1 or NF-κB to their respective DNA targets that lack the 5'-ACGTG-3' core structure in cell-free EMSA assays. Reversibly inhibits hypoxia-induced HIF-1 transcription activity in an HRE promoter-based reporter assay in U215 cells (EC50 = 1.2 nM) and is of no effect against SV40 promoter-driven transcription activity. Despite echinomycin's in vitro apoptosis-inducing activity and the initial report of its in vivo antitumor effect in mice, clinical trials have not yet resulted in promising data regarding its therapeutic efficacy in cancer treatment.
      Catalogue Number330175
      Brand Family Calbiochem®
      SynonymsNSC-13502, Quinomycin A
      References
      ReferencesPark, J.Y., et al. 2008. Cell. Biol. Int. 32, 1207.
      Kong, D., et al. 2005. Cancer Res. 65, 9047.
      Chang, A.Y., et al. 1998. Cancer 82, 292.
      Wadler, S., et al. 1994. Cancer Chemother. Pharmacol. 34, 266.
      Muss, H.B., et al. 1993. Am. J. Clin. Oncol. 16, 492.
      Foster, B.J., et al. 1985. Invest. New Drugs 3, 403.
      Van Dyke, N.M., et al. 1984. Science 225, 1122.
      Ward, D.C., et al. 1965. Science 149, 1259.
      Product Information
      CAS number512-64-1
      FormWhite to off-white to fawn solid
      Hill FormulaC₅₁H₆₄N₁₂O₁₂S₂
      Chemical formulaC₅₁H₆₄N₁₂O₁₂S₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 23/24/25-46

      Toxic by inhalation, in contact with skin and if swallowed.
      May cause heritable genetic damage.
      S PhraseS: 36-36/37/39-45-53

      Wear suitable protective clothing.
      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Avoid exposure - obtain special instructions before use.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Toxic
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C.) Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Echinomycin Streptomyces sp. - CAS 512-64-1 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Echinomycin Streptomyces sp. - CAS 512-64-1 - Calbiochem Certificates of Analysis

      TitleLot Number
      330175

      References

      Reference overview
      Park, J.Y., et al. 2008. Cell. Biol. Int. 32, 1207.
      Kong, D., et al. 2005. Cancer Res. 65, 9047.
      Chang, A.Y., et al. 1998. Cancer 82, 292.
      Wadler, S., et al. 1994. Cancer Chemother. Pharmacol. 34, 266.
      Muss, H.B., et al. 1993. Am. J. Clin. Oncol. 16, 492.
      Foster, B.J., et al. 1985. Invest. New Drugs 3, 403.
      Van Dyke, N.M., et al. 1984. Science 225, 1122.
      Ward, D.C., et al. 1965. Science 149, 1259.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision29-August-2019 JSW
      SynonymsNSC-13502, Quinomycin A
      DescriptionA cell-permeable Streptomyces-derived antibiotic that contains two bicyclic peptide-linked quinoxalines and acts as a sequence-specific DNA bisintercalator. Echinomycin at 10 µM is shown to inhibit HIF-1 and Myc/Max DNA binding activities in U251 and MCF-7 nuclear extracts by >90%, while exhibiting little effect against the binding of AP-1 or NF-κB to their respective DNA targets that lack the 5'-ACGTG-3' core structure in cell-free EMSA assays. Reversibly inhibits hypoxia-induced HIF-1 transcription activity in an HRE promoter-based reporter assay in U215 cells (EC50 = 1.2 nM) and is of no effect against SV40 promoter-driven transcription activity. Despite echinomycin's in vitro apoptosis-inducing activity and the initial report of its in vivo antitumor effect in mice, clinical trials have not yet resulted in promising data regarding its therapeutic efficacy in cancer treatment.
      FormWhite to off-white to fawn solid
      CAS number512-64-1
      Chemical formulaC₅₁H₆₄N₁₂O₁₂S₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C.) Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Toxic
      ReferencesPark, J.Y., et al. 2008. Cell. Biol. Int. 32, 1207.
      Kong, D., et al. 2005. Cancer Res. 65, 9047.
      Chang, A.Y., et al. 1998. Cancer 82, 292.
      Wadler, S., et al. 1994. Cancer Chemother. Pharmacol. 34, 266.
      Muss, H.B., et al. 1993. Am. J. Clin. Oncol. 16, 492.
      Foster, B.J., et al. 1985. Invest. New Drugs 3, 403.
      Van Dyke, N.M., et al. 1984. Science 225, 1122.
      Ward, D.C., et al. 1965. Science 149, 1259.